Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | UCARTCS1: a novel allogeneic CAR-T therapy for myeloma

Roman Galetto • 14 May 2022
COMy 2022
Multiple Myeloma CAR-T

Roman Galetto, PhD, Cellectis, Paris, France, briefly discusses UCARTCS1, a novel allogeneic chimeric antigen receptor T-cell (CAR-T) therapy developed for the treatment of multiple myeloma. Dr Galetto also highlights the challenges associated with developing CAR-T products that target CS1, and the benefits of using this novel approach for the treatment of myeloma. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Cellectis employee

More from Roman Galetto

0:51
Novel allo-CART therapies and their role in the treatment of hematological malignancies
Roman Galetto • 14 May 2022
1:09
Using TALEN gene editing to improve the efficacy of T-cell therapies
Roman Galetto • 14 May 2022

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals